One of the biggest hurdles scientists and drug developers face is being able to deliver effective treatments to the brain in sufficient quantities to have a meaningful clinical effect. Crossing the blood-brain barrier requires significant advancement in order to make progress in the treatment of these devastating diseases.
AB126 is the solution
Aruna Bio’s AB126 therapeutic exosome has CNS specificity.
The outer surface of AB126 is equipped with receptors and surface proteins that the brain recognizes, permitting it to cross the blood-brain barrier.
Concentration of AB126 exosomes in the brain
90 Minutes: Coronal mouse brain sections with labeled AB126
6 and 24 Hours: Greater intensity throughout the brain and concentration in the cerebellum and basal ganglia
Life changing possibilities as a therapeutic agent
In many neurodegenerative diseases, inflammatory lymphocytes generate an autoimmune attack on brain white matter, leading to neuro-inflammation, axon destruction, and neuronal death. These effects, in turn, often result in progressive disability over time.
Unlike other treatments, AB126 may be able to target many of the pathophysiologic mechanisms associated with neurodegenerative diseases, through its innate potential to reduce neuro-inflammation, stimulate neuro-regeneration, and promote neuroprotection.
In parallel to these possibilities are some certainties. We have the technology to manufacture our neural-derived exosomes using a scalable process that allows the production of large quantities of neural exosomes with consistency and uniformity.
Aruna has strong expertise in purifying and concentrating exosomes
Our valuable know-how and trade secrets allow us to excel at the difficult process of isolating, purifying, and concentrating exosomes from media
Aruna has an in-house cGMP facility, which is currently scaling-up for production of clinical material
We will have the ability to manufacture clinical grade batches, ultimately scale to Phase 3 trials, and potentially produce commercial batches
.png)
